{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:43:01Z","timestamp":1784619781773,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T00:00:00Z","timestamp":1283990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:sec><jats:label\/><jats:p>Eur J Clin Invest 2010; 40 (12): 1104\u20131112<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The aim of this study was to estimate the resource implications and budget impact of managing adults with Fabry disease in Norway, from the perspective of the publicly funded healthcare system.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A decision model was constructed using published clinical outcomes and clinician\u2010derived resource utilization estimates. The model was used to estimate the annual healthcare cost of managing a cohort of 64 adult Fabry patients in an average year.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The expected annual cost of managing 60 existing Fabry patients and four new patients in Norway each year was estimated to be NOK 55\u00b78 million (\u20ac6\u00b77 million). In an average year, patients receiving enzyme replacement therapy (ERT) with agalsidase alfa (Replagal<jats:sup>\u00ae<\/jats:sup>) at 0\u00b72\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> or agalsidase beta (Fabrazyme<jats:sup>\u00ae<\/jats:sup>) at 1\u00b70\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> are collectively expected to make 586 attendances to their family practitioner\u2019s office for their infusions, which equates to 128 eight\u2010hour days associated with ERT. Encouraging more patients to undergo home\u2010based infusions has substantial potential to free\u2010up community\u2010based resources. In comparison, the community\u2010related benefit that can be obtained by switching from agalsidase beta (1\u00b70\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) to agalsidase alpha (0\u00b72\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) is marginal, and dependent on the two doses being clinically equivalent.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Maximizing the proportion of adults with Fabry disease undergoing home\u2010based infusions has the potential to release community\u2010based resources for alternative use by non\u2010Fabry patients, thereby improving the efficiency of the publicly funded healthcare system in Norway.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2362.2010.02363.x","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T08:58:36Z","timestamp":1284022716000},"page":"1104-1112","source":"Crossref","is-referenced-by-count":10,"title":["Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion"],"prefix":"10.1111","volume":"40","author":[{"given":"Julian F.","family":"Guest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trond","family":"Jenssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Houge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Aaseboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03554-6"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-003-1299-3"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.065904"},{"key":"e_1_2_8_6_2","unstructured":"European Organisation for Rare Diseases2009. Available athttp:\/\/www.eurordis.org\/article.php3?id_article=1504. Accessed on 30 September 2009."},{"key":"e_1_2_8_7_2","first-page":"37","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Desnick RJ","year":"2001"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.249"},{"key":"e_1_2_8_9_2","first-page":"1004","article-title":"Fabry disease \u2013 a diagnostic and therapeutic challenge","volume":"125","author":"Houge G","year":"2005","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(98)90023-6"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1552-6569.2001.tb00051.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc3801.096352"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/hs0202.102601"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008080870"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712590802658428"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2004.025791"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000009948.86528.72"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200303203481224"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006080816"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00148"},{"key":"e_1_2_8_21_2","volume-title":"Health Systems in Transition: Norway","author":"Johnsen JR","year":"2006"},{"key":"e_1_2_8_22_2","unstructured":"NAV2009. Available on line athttp:\/\/www.nav.no. Accessed on 30 September 2009."},{"key":"e_1_2_8_23_2","unstructured":"OECD Health Data2008. Available online athttp:\/\/www.oecd.org\/health. Accessed on 30 September 2009."},{"key":"e_1_2_8_24_2","first-page":"e273","article-title":"Evidence and values: requirements for public reimbursement of drugs for rare diseases \u2013 a case study in oncology","volume":"16","author":"Drummond M","year":"2009","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi221"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2006.15.6.20681"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwg034"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-005-0342-9"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05816-0"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12357-4"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000069509.57929.CD"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.7.1167"},{"key":"e_1_2_8_33_2","first-page":"354","article-title":"Enzyme replacement therapy in Fabry\u2019s disease: recent advances and clinical applications","volume":"17","author":"Mignani R","year":"2004","journal-title":"J Nephrol"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.21.2743"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10497"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi152"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168482"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/422366"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000091253.71282.04"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00284.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01237.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000598"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181a23bec"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e318170f868"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2010.02363.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2010.02363.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T12:29:59Z","timestamp":1698755399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2010.02363.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,9]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1365-2362.2010.02363.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2010.02363.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,9]]}}}